“MASLD and T2DM represent intersecting global epidemics with substantial clinical and public health implications,” wrote the ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) can cause more serious liver conditions, such as liver failure. A new study, led by Lund University in Sweden, presents new data that ...

BOSTON — In the staging of liver fibrosis in the post-liver transplant setting, readings from noninvasive tests commonly have major discrepancies when compared with liver biopsy results, particularly ...

A diagnosis of serious liver disease can feel like a slow countdown. Scar tissue builds quietly, the liver stiffens, and the ...

Liver disease includes any condition that damages your liver. Over time, scar tissue can build up in your liver. Scarring or fibrosis can progress over many years until you develop cirrhosis—the most ...

A significant number of people had asymptomatic liver disease, according to a large-scale European study. The LIVERSCREEN study is assessing a feasible, non-invasive screening strategy for liver ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) can cause more serious liver conditions, such as liver failure. A new study, led by ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

At present, transient elastography and the serum marker FibroTest are the most intensively evaluated non-invasive methods for the assessment of liver fibrosis. The results of the present study for ...

Semaglutide met both primary endpoints in part 1 of ESSENCE. Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic ...